MaxCyte trading ahead of expectations as CARMA programme progresses
Maxcyte Inc (DI/REG S)
925.00p
16:55 21/05/21
Cell-based therapies and life sciences company MaxCyte updated the market on its trading on Wednesday, reporting that based on ongoing momentum in cell therapies and milestone payments from growth in clinical and commercial licence partnerships, it was expecting financial results to be ahead of market expectations for the full-year in the core life sciences business, before costs of the CARMA programme.
Pharmaceuticals & Biotechnology
22,664.47
14:49 26/04/24
The AIM-traded firm said a more detailed trading update would be announced during the week of 18 January.
It said it was continuing to work with Locust Walk on the strategy and future funding of the CARMA business, with enrolment and dosing in the existing CARMA no-preconditioning MCY-M11 clinical study said to be continuing well.
The company said it would also provide an update on that in January.
“We have seen sustained strong growth in our core life sciences business as demand for our next generation gene and cell therapy enabling products continues to expand internationally, despite the issues that Covid-19 has placed around the globe,” said president and chief executive officer Doug Doerfler.
“MaxCyte continues to be uniquely positioned to capitalise on the rapidly growing cell therapy market.”
At 0923 GMT, shares in MaxCyte were up 7.43% at 489.9p.